ASX Announcement

Results of Annual General Meeting

20 November 2026

Ceretas Limited (ASX: CTS) (Company) advises that in accordance with ASX Listing Rule 3.13.2 and Section 251AA of the Corporations Act, details of the resolutions and proxies received for the Annual General Meeting held on 20 November 2026.

No.	Resolution	Results on a poll
1.	Remuneration Report	Carried
2.	Re-election of Stuart Crozier as Director	Carried
3.	Approval of potential termination benefits	Carried
4.	Appointment of auditor	Carried
5.	Approval of 10% Placement Facility	Carried

Proxies received and the results of the poll are shown on the attached Schedule.

This announcement is authorised for release by the Board of Directors.

- ENDS -

For further information please contact

Henry Jordan
Six Degrees Investor Relations
henry.jordan@sdir.com.au
+61 (0)431 271 538

Dr Rachel de las Heras
Chief Executive Officer & Managing Director
racheldelasheras@ceretas.com.au
+61 (0)437 338 079

About Ceretas

Ceretas (ASX:CTS) is a clinical-stage medical technology company developing a portable, non-invasive therapeutic ultrasound platform to treat Alzheimer's disease and other neurodegenerative conditions.

The Ceretas device directs low-intensity focused ultrasound through the skull to act on brain tissue via two mechanisms: neuromodulation, targeting neural circuits involved in memory, cognition and the behavioural and psychological symptoms of dementia; and blood-brain barrier opening, which may facilitate clearance of disease-associated proteins and enhance delivery of therapeutic agents to the brain.

The technology is based on more than a decade of research at The University of Queensland and the Queensland Brain Institute (QBI). In 2024, QBI researchers completed a first-in-human Phase 1 trial of low-intensity focused ultrasound neuromodulation in 12 Alzheimer's participants, finding the treatment to be fast, safe and well tolerated, with encouraging early signals of benefit for behavioural symptoms. The results were published in Brain Communications in December 2025.

Ceretas is preparing to commence its Phase 2 CERE-CALM trial (ACTRN12626000738325), evaluating the platform in Alzheimer's patients with behavioural and psychological symptoms of dementia. QBI researchers are separately running their Phase 2 AGIFUS trial (ACTRN12626000687392), evaluating the same technology in Alzheimer's-related agitation, funded independently by Queensland Health.

Results of Meeting

Ceretas Limited

Annual General Meeting

Friday, 20 November 2026

Automic
GPO Box 5193, Sydney, NSW 2001
P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)
F +61 (0)2 8583 3040 E hello@automic.com.au
ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

		Proxy Votes (as at proxy voting close)				Poll Results (if applicable)			Results
Resolution	**Decided by Show of Hands (S) or Poll (P)**	**FOR**	**AGAINST**	**ABSTAIN**	**PROXY'S DISCRETION**	**FOR**	**AGAINST**	**ABSTAIN**	**OUTCOME**
1 Remuneration Report	P	21,714,832 99.64%	78,000 0.36%	11,250	1,414 0.01%	22,314,547 99.65%	78,000 0.35%	11,250	-
2 Re-election of Stuart Crozier as Director	P	34,354,246 100.00%	0 0.00%	11,250	0 0.00%	35,083,547 100.00%	0 0.00%	11,250	Carried
3 Approval of potential termination benefits	P	24,590,165 96.28%	86,000 0.34%	14,331	865,000 3.39%	26,053,466 99.67%	86,000 0.33%	14,331	Carried
4 Appointment of auditor	P	34,365,496 100.00%	0 0.00%	0	0 0.00%	35,094,797 100.00%	0 0.00%	0	Carried
5 Approval of 10% Placement Facility	P	34,283,001 99.77%	78,000 0.23%	3,081	1,414 0.00%	35,013,716 99.78%	78,000 0.22%	3,081	Carried